Eiger BioPharmaceuticals, Inc.
EIGR
Hisse Senetlerindeki Sıralama
#36465
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Hisse Fiyatı
$1.73
Son senkronizasyon: 2025-06-17
Piyasa Değeri
$2.55M
Değişim (1 gün)
-0.29%
Değişim (1 yıl)
-79.71%
Ülke
US
Ticaret Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
Eiger BioPharmaceuticals, Inc. (EIGR) için P/S oranı
October 2026 itibarıyla P/S oranı TTM: 0.80
Eiger BioPharmaceuticals, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 0.80'dir. 2022 yılının sonunda şirketin P/S oranı 3.64 idi.
Eiger BioPharmaceuticals, Inc. için P/S oranı geçmişi 2016 - 2026 arası
Her yılın sonunda P/S oranı
| Yıl | P/S Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 0.80 | 20.91% |
| 2023 | 0.66 | -81.89% |
| 2022 | 3.64 | -74.89% |
| 2021 | 14.51 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Benzer şirketler veya rakipler için P/S oranı
| Şirket | P/S Oranı | P/S Oranı Farkı | Ülke |
|---|---|---|---|
| 10.02 | 1,155.90% |
US
|
|
| 40.55 | 4,981.55% |
US
|
|
| 3.96 | 396.38% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 1,171.47% |
NL
|
